Substance / Medication

Cantharidin

Overview

Active Ingredient
cantharidin
RxNorm CUI
1984

Indications

YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

Labeler: Verrica Pharmaceuticals Inc.Updated: 2024-11-13T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bibliometric Analysis and Systemic Review of Cantharidin Research Worldwide.
He Tianmu, Duan Cancan, Feng Wenzhong et al. · Curr Pharm Biotechnol · 2024
PMID: 39034837Meta-Analysis
Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
Vakharia Paras P, Chopra Rishi, Silverberg Nanette B et al. · Am J Clin Dermatol · 2018
PMID: 30097988Meta-Analysis
Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial.
Recanati Maurice A, Kramer Katherine J, Maggio John J et al. · Clin Exp Obstet Gynecol · 2018
PMID: 30078935RCTFull text (PMC)
Treatment of mid-late stage NSCLC using sodium cantharidinate/vitamin B6/GP regimen in clinic.
Wang Baoli, Cui Jiandong · J Cancer Res Ther · 2014
PMID: 25207898RCT
Cantharidin-podophylotoxin-salicylic acid versus cryotherapy in the treatment of plantar warts: a randomized prospective study.
Kaçar N, Taşlı L, Korkmaz S et al. · J Eur Acad Dermatol Venereol · 2012
PMID: 21790794RCT
[Efficacy of cantharidin combined with transcatheter arterial embolization for primary hepatocellular carcinoma].
Wu Zhen-ming, Liu Qi, Qi Xiu-heng · Nan Fang Yi Ke Da Xue Xue Bao · 2010
PMID: 21341532RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cantharidin (substance)
SNOMED CT
86218002
UMLS CUI
C0006886
RxNorm CUI
1984
Labeler
Verrica Pharmaceuticals Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.